Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer

Nikolaos Xenidis,K. Neanidis,K. Amarantidis,P. Dimopoulos,E. Chamalidou,D. Pitsiava,Antonios-Apostolos K. Tentes,Ekaterini Chatzaki,Petros Karakitsos,Stylianos Kakolyris

Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer

2011

Nikolaos Xenidis
K. Neanidis
K. Amarantidis
P. Dimopoulos
E. Chamalidou
D. Pitsiava
Antonios-Apostolos K. Tentes
Ekaterini Chatzaki
Petros Karakitsos
Stylianos Kakolyris

Purpose To evaluate the activity and tolerance of vinorelbine (VRL) in combination with gemcitabine (GEM) in pre-treated patients with refractory ovarian cancer.

Keywords:

Refractory
Ovarian cancer
Stable Disease
Vinorelbine
Performance status
Oncology
Gemcitabine
Progressive disease
Internal medicine
Medicine
second line
pharmacology toxicology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations